Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia
The purpose of this study is to determine the safety and acceptability of the experimental drug Samalizumab when administered with standard treatment for acute myeloid leukemia (AML).
Acute Myeloid Leukemia (AML)
-Participating in the Beat AML umbrella study master protocol (reference IRB# 16475)
-Newly diagnosed with AML
-Age 60 years or older at time of diagnosis
60 - n/a
Healthy Volunteers Needed
Duration of Participation
Study participation may include up to 2 years of study drug treatment and 28 days after you stop taking the study drug.
Clinical Trials Information Line
Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc
Supported by: Alexion Pharmaceuticals